Need for Spasticity Agents

Rønning OM, Tornes KD.Need for symptomatic management in advanced multiple sclerosis. Acta Neurol Scand. 2016. doi: 10.1111/ane.12631. [Epub ahead of print]

OBJECTIVE:A majority of patients with advanced multiple sclerosis (MS) need symptomatic treatment. Many MS-related symptoms may not be recognized and thus are not treated. We conducted a study to estimate the prevalence of inadequate symptomatic treatment of patients with advanced MS.
METHODS:Patients with advanced MS admitted to a specialist MS rehabilitation clinic were included in this study. Severity was assessed using the Expanded Disability Status Scale (EDSS). The information we collected included age of onset, initial course, time to sustained disability, pharmacological treatment, degree of spasticity, pain and bladder dysfunction, and unmet needs of symptomatic treatment.
RESULTS: In total, we assessed demographic and clinical characteristics in 129 patients with a mean age of 56 years and a median EDSS of 7.5. The proportion with inadequate symptom treatment was regarding spasticity 46%, pain 28%, and bladder dysfunction 23%.
DISCUSSION:This study showed that a large proportion of patients with advanced MS had lack of symptomatic treatment. These patients probably under use neurological specialist services. Better symptomatic treatment could contribute to improving quality of life of people with MS

This paper says that nearly 50% of people with disability due to MS get inadequate control of their spasticity. So we need more effective anti-spastic agents. We have been developing one and have an ongoing clinical trial.

CoI We are developing and anti-spastic agent

About the author


Add comment

By MouseDoctor



Recent Posts

Recent Comments